ArticlePCN reports : psychiatry and clinical neurosciences2025
New-onset Kleine-Levin syndrome following COVID-19 infection: A case report.
Article in PCN reports : psychiatry and clinical neurosciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- New-onset Kleine-Levin syndrome following COVID-19 infection: A case report.PCN reports : psychiatry and clinical neurosciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Kleine-Levin syndrome (KLS) is a rare sleep disorder marked by recurrent episodes of severe hypersomnolence with accompanying cognitive, behavioral, or mood disturbances. Infections are frequently reported before symptom onset and have been proposed as potential triggers, although a definitive causal relationship has not been established. Although relapses of KLS after COVID-19 infection have been described, only one possible case of new-onset KLS associated with COVID-19 has been reported, in which a definitive diagnosis was not established. Case Presentation: We describe a 17-year-old male who developed KLS following a confirmed COVID-19 infection. After his clinical recovery, he began experiencing hypersomnolent episodes every few months, each lasting approximately 2 weeks and accompanied by decreased motivation and appetite. As the illness progressed, he developed persistent nausea lasting several weeks before each hypersomnolent episode, suggesting the emergence of a prodromal phase. Treatment with lithium and adjunctive modafinil showed limited efficacy in preventing recurrence or reducing episode severity. Each complete cycle comprising prodromal, hypersomnolent, and recovery phases lasted over a month and significantly disrupted his academic and social functioning. Conclusion: This case represents the first diagnostically confirmed report of new-onset KLS following COVID-19 infection and suggests a possible autoimmune mechanism triggered by SARS-CoV-2. These findings emphasize the importance of comprehensive clinical assessment beyond objective test results and underscore the urgent need for effective treatment strategies tailored to the heterogeneous and disabling nature of KLS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.